A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

ABSTRACT:

Background

The European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality.

Objective

To determine whether PSA screening decreases PCa mortality for up to 16yr and to assess results following adjustment for nonparticipation and the number of screening rounds attended.

Design, setting, and participants

This multicentre population-based randomised screening trial was conducted in eight European countries. Report includes 182160 men, followed up until 2014 (maximum of 16yr), with a predefined core age group of 162389 men (55-69yr), selected from population registry.

Outcome measurements and statistical analysis

The outcome was PCa mortality,

SUBMITTER: Hugosson J 

PROVIDER: S-EPMC7513694 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature